The TheraBionic device uses radiofrequency electromagnetic fields delivered by a spoon-shaped antenna in the patient’s mouth to treat advanced hepatocellular cancer.
Hepatocellular carcinoma is the most common form of liver cancer, with an average survival rate between six to twenty months. In the large majority of cases, it is connected to long-term liver disease. Common causes include hepatitis B, hepatitis C, and alcohol consumption. Often, it is slow to be detected because it has very few or no symptoms until its advanced stages, when it becomes much harder to treat.
The TheraBionic P1 is a treatment for the cancer in patients who have already undergone common therapies which have failed or cannot tolerate specific treatment regimes. This includes those who cannot tolerate cancer growth blocker drugs such as sorafenib, or immunotherapy.
The TheraBionic P1 delivers radiofrequency electromagnetic fields through a spoon-shaped antenna placed on the tongue. The body then absorbs these. The patient uses the device for sixty minutes a session, three times a day. The treatment does not affect the growth of healthy cells while blocking the growth of tumour cells. By emitting radio waves at precise frequencies, cancer growth can be stopped for a certain period, either causing shrinkage of the tumour or stopping further progression. Numerous studies have been undertaken with the device, demonstrating some benefits.
The electromagnetic therapy device is used at home and comes with a carry case for portability. During use, the patient should experience no symptoms or side-effects. The cofounders of TheraBionic Inc are aiming to find safer, better cancer therapies. They continue to research the application of radiofrequency electromagnetic field therapy as a form of low-risk treatment for other types of cancers.